Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,748 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03156114 | This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. | completed | Phase 1 | 172 | Boehringer IngelheimINDUSTRY | 5 | Jan 26, 2026 | clinicaltrials |
| NCT04139434 | Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML | completed | Phase 1 | 32 | Newave Pharmaceutical IncINDUSTRY |
| 2 |
| Jan 23, 2026 |
| clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT03994601 | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | completed | Phase 1 / Phase 2 | 219 | Bristol-Myers SquibbINDUSTRY | 7 | Jan 20, 2026 | clinicaltrials |
| NCT06359002 | Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms. | active not recruiting | Phase 1 | 16 | Byondis B.V.INDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT04183166 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | TransgeneINDUSTRY | 4 | Jan 16, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients(MINDway) | active not recruiting | Phase 1 / Phase 2 | 53 | Incyte CorporationINDUSTRY | 9 | Jan 16, 2026 | clinicaltrials |
| NCT05737628 | First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | active not recruiting | Phase 1 | 17 | Byondis B.V.INDUSTRY | 4 | Jan 16, 2026 | clinicaltrials |
| NCT06879717 | A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients(PULMO-01) | active not recruiting | Phase 1 / Phase 2 | 45 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT06932952 | A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 7 | Byondis B.V.INDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT07231458 | A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies | recruiting | Phase 1 | 27 | Abalos Therapeutics GmbHINDUSTRY | 2 | Jan 16, 2026 | clinicaltrials |
| NCT05375903 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 1 | 51 | UroGen Pharma Ltd.INDUSTRY | 3 | Jan 14, 2026 | clinicaltrials |
| NCT06059001 | Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC(OMO-103-02) | active not recruiting | Phase 1 | 26 | Peptomyc S.L.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | active not recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jan 13, 2026 | clinicaltrials |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients(RAMP203) | active not recruiting | Phase 1 / Phase 2 | 153 | Verastem, Inc.INDUSTRY | 6 | Jan 12, 2026 | clinicaltrials |
| NCT05209295 | A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies | terminated | Phase 1 | 2 | Bristol-Myers SquibbINDUSTRY | 5 | Jan 12, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT06163430 | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)(CARDINAL) | recruiting | Phase 1 / Phase 2 | 180 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 9 | Jan 12, 2026 | clinicaltrials |
| NCT02988960 | A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 163 | AbbVieINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | terminated | Phase 1 | 250 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Jan 9, 2026 | clinicaltrials |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | recruiting | Phase 1 / Phase 2 | 348 | Corbus Pharmaceuticals Inc.INDUSTRY | 7 | Jan 8, 2026 | clinicaltrials |
| NCT06631079 | Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 20 | NEC Bio B.VINDUSTRY | 3 | Jan 8, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT05830084 | Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma(REGO-INTER-EWI) | active not recruiting | Phase 1 | 23 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Jan 6, 2026 | clinicaltrials |
| NCT04240002 | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 9 | Astellas Pharma Global Development, Inc.INDUSTRY | 5 | Jan 5, 2026 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT02546661 | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer(BISCAY) | active not recruiting | Phase 1 | 117 | AstraZenecaINDUSTRY | 5 | Dec 29, 2025 | clinicaltrials |
| NCT01695005 | A Study of LY3039478 in Participants With Advanced Cancer | completed | Phase 1 | 247 | Eli Lilly and CompanyINDUSTRY | 6 | Dec 26, 2025 | clinicaltrials |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer(CheckMate040) | completed | Phase 1 / Phase 2 | 657 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 24, 2025 | clinicaltrials |
| NCT04123418 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | terminated | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 24, 2025 | clinicaltrials |
| NCT04294160 | A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 24, 2025 | clinicaltrials |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT06488716 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 12 | Genentech, Inc.INDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT05483933 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | completed | Phase 1 | 86 | Shattuck Labs, Inc.INDUSTRY | 4 | Dec 23, 2025 | clinicaltrials |
| NCT04936178 | A Study of NB003 in Patients With Advanced Malignancies | completed | Phase 1 | 258 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 6 | Dec 22, 2025 | clinicaltrials |
| NCT05499013 | Study to Assess SLN124 in Patients With Polycythemia Vera(SLN) | active not recruiting | Phase 1 / Phase 2 | 69 | Silence Therapeutics plcINDUSTRY | 9 | Dec 19, 2025 | clinicaltrials |
| NCT03573310 | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS | completed | Phase 1 | 114 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT06509906 | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) | terminated | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05652868 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 1 | 227 | Mythic TherapeuticsINDUSTRY | 7 | Dec 16, 2025 | clinicaltrials |
| NCT07284277 | TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) | recruiting | Phase 1 / Phase 2 | 30 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04009681 | A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)(HAMMER) | terminated | Phase 1 / Phase 2 | 175 | Synthorx, Inc, a Sanofi companyINDUSTRY | 6 | Dec 15, 2025 | clinicaltrials |
| NCT03310957 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 1 / Phase 2 | 185 | Seagen Inc.INDUSTRY | 4 | Dec 12, 2025 | clinicaltrials |
| NCT03595059 | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | completed | Phase 1 | 168 | AbbVieINDUSTRY | 10 | Dec 10, 2025 | clinicaltrials |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | completed | Phase 1 | 28 | AdaptimmuneINDUSTRY | 4 | Dec 9, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT03968653 | Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | terminated | Phase 1 | 76 | Debiopharm International SAINDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials